跳到正文
FDA 官方药品与生物制品信息·· 19 天前AI 评分47

FDA 发布《上市前活动进口请求(PLAIR)》最终指南

Importing Drugs with a Pre-Launch Activities Importation Request (PLAIR)

AI 导读

FDA 发布最终指南《上市前活动进口请求(PLAIR)》,说明在预期获批前允许药品申办者进口未获批成品药的政策与流程。PLAIR 一般应在用户费目标日前不超过 60 天提交,获优先审评认定的申请可提前至 120 天。申办者应通过 CDER NexGen Portal 提交以加快处理。

正文 · 原文

Human Drug Imports

Pre-approval importation requests

FDA reviews requests and may grant permission in certain circumstances for a manufacturer to import a drug in anticipation of the drug receiving FDA approval. When approved, these pre-launch activities importation requests, or PLAIRs, allow drug sponsors to import unapproved finished drugs in preparation for anticipated FDA approval and market launch. 

FDA’s final guidance, Pre-Launch Activities Importation Requests (PLAIR), describes this policy to help ensure timely access to safe and effective drugs.

The guidance describes FDA’s process for PLAIR requests to ensure control and tracking of unapproved drugs awaiting an anticipated FDA approval consistent with the FD&C Act. The policy generally describes that the PLAIR should be submitted no more than 60 days before the user-fee goal date but also allows some PLAIR submissions up to 120 days before the user-fee goal date if the application has a priority review designation.

Application sponsors should use the CDER NexGen Portal to expedite this process. The portal uses multi-factor authentication to ensure data security to protect the integrity of the drug supply chain. 

来源:FDA 官方药品与生物制品信息 · fda.gov